COX-2 selective inhibitors like celecoxib and etodolac also have been proved to be efficient in chemoprevention for non-melanoma skin cancers and gastric cancer (Elmets et al., 2010; Yanaoka et al., 2010). The gene discussed is PTGS2; the disease is gastric cancer.